SCHEMBL6844903

SCHEMBL6844903

NCCCOc1c(-c2ccoc2)ccc(CS(=O)(=O)c2ccccc2)c1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 6/20 0.39
ALOX5AP P20292 1/20 0.35
FABP4 P15090 1/20 0.34
FABP5 Q01469 1/20 0.34
NAT1 P18440 3/20 0.34
MCL1 Q07820 1/20 0.33
ITGB3 P05106 1/20 0.31
ITGA2B P08514 1/20 0.31
ALOX5 P09917 1/20 0.31
PLAU P00749 1/20 0.31
TSHR P16473 1/20 0.30
HSD17B10 Q99714 1/20 0.30
PPARD Q03181 1/20 0.30
PPARA Q07869 1/20 0.30
PTGES2 Q9H7Z7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1648362 0.99 METAP2 (0.39) METAP2ALOX5APFABP4FABP5NAT1
SCHEMBL1649388 0.96 METAP2 (0.39) METAP2ALOX5APFABP4FABP5NAT1
Hydrochloric Acid SCHEMBL1648336 0.95 METAP2 (0.39) METAP2ALOX5APFABP4FABP5NAT1
SCHEMBL1648728 0.92 METAP2 (0.41) METAP2ALOX5APFABP4FABP5NAT1
SCHEMBL1649915 0.89 METAP2 (0.43) METAP2FABP4FABP5NAT1MCL1
SCHEMBL1649172 0.88 METAP2 (0.39) METAP2ALOX5APFABP4FABP5NAT1
SCHEMBL1648269 0.88 METAP2 (0.43) METAP2FABP4FABP5NAT1MCL1
SCHEMBL1648645 0.87 METAP2 (0.42) METAP2FABP4FABP5NAT1MCL1
SCHEMBL1647731 0.87 METAP2 (0.42) METAP2FABP4FABP5NAT1MCL1
SCHEMBL6844852 0.87 METAP2 (0.50) METAP2ALOX5APFABP4FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS METAP2 1/4885ALOX5AP 1081/4885FABP4 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.